


PRODUCT: PIK-90

ALTERNATE NAMES:	PIK90; PIK 90; N-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide; N-(2,3-dihydro-7,8-dimethoxyimidazo[1,2-c]quinazolin-5-yl)-3-pyridinecarboxamide
CATALOG#:	B1671-5, -25
AMOUNT:	5 mg, 25 mg
STRUCTURE:	
MOLECULAR FORMULA:	C ₁₈ H ₁₇ N ₅ O ₃
MOLECULAR WEIGHT:	351.36
CAS NUMBER:	677338-12-4
APPEARANCE:	Solid powder
SOLUBILITY:	DMSO
PURITY:	>98%
STORAGE:	Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.
DESCRIPTION:	PIK-90 is a PI3K $\alpha/\gamma/\delta$ inhibitor with IC ₅₀ of 11 nM/18 nM/58 nM, respectively, less potent to PI3K β (IC ₅₀ = 350 nM).
HANDLING:	Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
REFERENCES:	<ol style="list-style-type: none">1. Van Keymeulen A1 et al. To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J Cell Biol. 2006 Jul 31;174(3):437-45.2. Zhang TT1 et al. Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production. J Allergy Clin Immunol. 2008 Oct;122(4):811-819.3. Cheng CK1 et al. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12722-7.

RELATED PRODUCTS:

- BEZ235 (NVP-BEZ235) (Cat. No. 1626-5, 25)
- GDC-0941 bismesylate (Cat. No. 1623-1, 5)
- Deforolimus (Cat. No. 1587-5, 25)
- IC87114 (Cat. No. 1661-1)
- LY 294002 (Cat. No. 1667-5, 25)
- mTOR Inhibitor, Ku-0063794 (Cat. No. 1779-1, 5)
- PI-103 (Cat. No. 1728-1, 5)
- PP242 (Cat. No. 1658-1)
- Rapamycin (Cat. No. 1568-5, 50)
- Temsirolimus (Cat. No. 1600-5, 25)
- TGX-115 (Cat. No. 1660-1)
- TGX-221 (Cat. No. 1781-1, 5)
- Wortmannin (Cat. No. 1670-1)

USAGE: *FOR RESEARCH USE ONLY! Not to be used in humans*